Occurrence in Plants and Biological Activities - a Review
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
-
Supporting Materials for Reappointment of Rong Di for 2004
CURRICULUM VITAE Rong Di Associate Research Professor Department of Plant Biology School of Environmental and Biological Sciences Rutgers University 222B Foran Hall, 59 Dudley Rd., New Brunswick, NJ 08901 Ph. (848)-932-6350, Fax (732)-932-9377 [email protected] http://plantbiology.rutgers.edu/faculty/di/Rong_Di.html July 2017 Appointments 2017-Present Associate Research Professor, Department of Plant Biology, School of Environmental and Biological Sciences, Rutgers University, New Brunswick, NJ 2011-2017 Assistant Research Professor, Department of Plant Biology and Pathology, School of Environmental and Biological Sciences, Rutgers University, New Brunswick, NJ 2014-Present Adjunct Professor, Hainan University, Hainan, China 2003-2011 Assistant Research Professor, Biotechnology Center for Agriculture and the Environment, School of Environmental and Biological Sciences, Rutgers University, New Brunswick, NJ 1997- 2002 Research Associate, Biotechnology Center for Agriculture and the Environment, School of Environmental and Biological Sciences, Rutgers University, New Brunswick, NJ 1992-1996 Postdoctoral Scholar, Dept. of Plant Pathology, and Dept. of Agronomy, University of Kentucky, Lexington, KY 1986-1992 Graduate Research Assistant, Dept. of Plant Pathology, Iowa State University, Ames, IA 1983-1985 Assistant Lecturer, Dept. of Plant Protection, South China College of Tropical Crops (SCCTC), Hainan, P. R. China Education Ph.D. 1992 Plant Virology, Iowa State University, Iowa (Advisor: W Allen Miller) M.S. 1989 Plant Virology, Iowa State University, Iowa (Advisor: John Hill) B.S. 1983 Plant Protection, South China College of Tropical Crops, Hainan, P.R. China Honors and Awards 1985 Selected as the only one among 45 graduates in the Dept. of Plant Protection from SCCTC China to study abroad. -
Pinoresinol Reductase 1 Impacts Lignin Distribution During Secondary Cell Wall Biosynthesis in Arabidopsis
Phytochemistry xxx (2014) xxx–xxx Contents lists available at ScienceDirect Phytochemistry journal homepage: www.elsevier.com/locate/phytochem Pinoresinol reductase 1 impacts lignin distribution during secondary cell wall biosynthesis in Arabidopsis Qiao Zhao a, Yining Zeng b,e, Yanbin Yin c, Yunqiao Pu d,e, Lisa A. Jackson a,e, Nancy L. Engle e,f, Madhavi Z. Martin e,f, Timothy J. Tschaplinski e,f, Shi-You Ding b,e, Arthur J. Ragauskas d,e, ⇑ Richard A. Dixon a,e,g, a Plant Biology Division, Samuel Roberts Noble Foundation, 2510 Sam Noble Parkway, Ardmore, OK 73401, USA b Biosciences Center, National Renewable Energy Laboratory, Golden, CO 80401, USA c Department of Biological Sciences, Northern Illinois University, DeKalb, IL 60115, USA d Institute of Paper Science and Technology, Georgia Institute of Technology, Atlanta, GA, USA e BioEnergy Science Center (BESC), Oak Ridge National Laboratory, Oak Ridge, TN 37831, USA f Biosciences Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831, USA g Department of Biological Sciences, University of North Texas, Denton, TX 76203, USA article info abstract Article history: Pinoresinol reductase (PrR) catalyzes the conversion of the lignan (À)-pinoresinol to (À)-lariciresinol in Available online xxxx Arabidopsis thaliana, where it is encoded by two genes, PrR1 and PrR2, that appear to act redundantly. PrR1 is highly expressed in lignified inflorescence stem tissue, whereas PrR2 expression is barely detect- Keywords: able in stems. Co-expression analysis has indicated that PrR1 is co-expressed with many characterized Lignan genes involved in secondary cell wall biosynthesis, whereas PrR2 expression clusters with a different Lignin set of genes. -
Nutraceuticals Brian Lockwood
CjigVXZji^XVah HZXdcYZY^i^dc 7g^VcAdX`lddY 00 Prelim 2/3/07 18:51 Page i Nutraceuticals 00 Prelim 2/3/07 18:51 Page ii 00 Prelim 2/3/07 18:51 Page iii Nutraceuticals A guide for healthcare professionals Second edition Brian Lockwood BPharm, PhD, MRPharmS Senior Lecturer in Pharmacy, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK London • Chicago 00 Prelim 2/3/07 18:51 Page iv Published by the Pharmaceutical Press An imprint of RPS Publishing 1 Lambeth High Street, London SE1 7JN, UK 100 South Atkinson Road, Suite 200, Grayslake, IL 60030–7820, USA © Pharmaceutical Press 2007 is a trade mark of RPS Publishing RPS Publishing is the publishing organisation of the Royal Pharmaceutical Society of Great Britain First edition published 2002 Second edition published 2007 Typeset by Type Study, Scarborough, North Yorkshire Printed in Great Britain by TJ International, Padstow, Cornwall ISBN 978 0 85369 659 9 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without the prior written permission of the copyright holder. The publisher makes no representation, express or implied, with regard to the accuracy of the information contained in this book and cannot accept any legal responsibility or liability for any errors or omissions that may be made. The right of Brian Lockwood to be identified as the author of this work has been asserted by him in accordance with sections 77 and 78 and subject to section 79(6) of the Copyright, Designs and Patents Act, 1988. -
Selective Estrogen Receptor Modulators for BPH: New Factors on the Ground
Prostate Cancer and Prostatic Disease (2013) 16, 226–232 & 2013 Macmillan Publishers Limited All rights reserved 1365-7852/13 www.nature.com/pcan REVIEW Selective estrogen receptor modulators for BPH: new factors on the ground M Garg1, D Dalela1, D Dalela1, A Goel1, M Kumar1, G Gupta2 and SN Sankhwar1 As the current management of BPH/lower urinary tract symptoms by traditionally involved pharmacological agents such as 5alpha- reductase inhibitors and a1-adrenoceptor antagonists is suboptimal, there is definite need of new therapeutic strategies. There is ample evidence in literature that suggests the role of estrogens in BPH development and management through the different tissue and cell-specific receptors. This article reviews the beneficial actions of selective estrogen receptor modulator (SERM) and ERb- selective ligands, which have been demonstrated through in vitro studies using human prostate cell lines and in vivo animal studies. SERMs have anti-proliferative, anti-inflammatory and pro-apoptotic mechanisms in BPH, and also act by inhibiting various growth factors, and thus represent a unique and novel approach in BPH management directed at estrogen receptors or estrogen metabolism. Prostate Cancer and Prostatic Disease (2013) 16, 226–232; doi:10.1038/pcan.2013.17; published online 18 June 2013 Keywords: selective estrogen receptors modulators; BPH; estradiol; estrogen receptor b INTRODUCTION relevant articles were selected for the discussion of role of SERMs in BPH in BPH is a common urological problem of aging males. It occurs in this review. about 10% of men below the age of 40 and increases to about 80% by 80 years of age.1 Clinical BPH is a benign enlargement of the prostate, which ESTROGENS AND ITS RECEPTORS: ROLE IN BPH results in voiding urinary difficulties that may, sometimes, Though BPH typically manifests in later stage of life when 2 significantly impair the quality of life in older patients. -
Medicinal Properties of Selected Asparagus Species: a Review Polo-Ma-Abiele Hildah Mfengwana and Samson Sitheni Mashele
Chapter Medicinal Properties of Selected Asparagus Species: A Review Polo-Ma-Abiele Hildah Mfengwana and Samson Sitheni Mashele Abstract Asparagus species are naturally distributed along Asia, Africa, and Europe and are known to have numerous biological properties. This review article was aimed to provide an organized summary of current studies on the traditional uses, phy- tochemistry, and pharmacological and toxicological studies of Asparagus laricinus Burch., Asparagus africanus Lam., Asparagus officinalis L., Asparagus racemosus Willd., and Asparagus densiflorus (Kunth) Jessop to attain and establish new insights for further researches. Information used in this review was obtained from electronic database including PubMed central, Google scholars, Science direct, Scopus, and Sabinet. Based on the present findings, the existing literature still presents some breaches about the mechanism of action of various constituents of these plants, and their relation to other plant compounds in poly-herbal formulations, as well as their long-term use and safety. More in-depth studies are still needed for active compounds and biological activities of Asparagus laricinus, Asparagus africanus, and Asparagus densiflorus. Therefore, innumerable opportunities and possibilities for investigation are still available in novel areas of these plants for future research stud¬ies. It can be concluded that all selected Asparagus species have tremendous potential to improve human health and the pharmacological activities of these plants can be attributed to bioactive phytochemicals they possess. Keywords: Asparagaceae, Asparagus africanus lam., Asparagus densiflorus (kunth) Jessop, Asparagus laricinus Burch., Asparagus officinalis L., Asparagus racemosus Willd., pharmacological actions, phytochemistry 1. Introduction Historically, plants were used for numerous purposes for mankind in general, inter alia, feeding and catering, culinary spices, medicine, various forms of cosmetics, symbols in worship and for a variety of ornamental goods. -
Anticancer Activity of Lignan from the Aerial Parts of Saussurea Salicifolia (L.) DC
Vol. 27, 2009, Special Issue Czech J. Food Sci. Anticancer Activity of Lignan from the Aerial Parts of Saussurea salicifolia (L.) DC. G. CHUNSRiiMYATAV1, 2*, I. HOZA1, P. VALÁšEK1, S. SKROVANKOVÁ1, D. BANZRAgcH2 and N. TsEVEgsUREN3 1Department of Food Engineering, Tomas Bata University in Zlin, 760 01 Zlín, Czech Republic; 2 Institute of Chemistry and Chemical Technology, Mongolian Academy Sciences, Ulaanbaatar, MON 51 Mongolia; 3Department of Organic Chemistry, Faculty of Chemistry, National University of Mongolia, Ulaanbaatar, Mongolia, *E-mail: [email protected] Abstract: Aerial parts of Saussurea salicifolia (L.) DC were studied for their lignan and flavonoids in solvent chloroform and n-butanol of ethanolic extract. Isolation and identification of phenolic compounds of the chloroform and n-butanol fractions were performed with Dionex HPLC-DAD system with water-methanol gradients in 4 different wave lengths (235 nm, 254 nm, 280 nm and 340 nm), using online UV and LC-MS as described previously. 9-OH-pinoresinol which is a lignan with anticancer activity was dominated in the chloroform fraction, whereas mainly flavonoid glycosides like quercetin-3-O-galactoside, apigenin-7-O-rhamnoside with anti-inflammatory effect were detected in the n-butanol fraction. Additionally, 9-OH-pinoresinol was also found in the n-butanol fraction. Anticancer tests were conducted in leukemia mouse lymphoma cells L5178Y at a concentration of 10 μg/ml of test compound. Crude ethanol extract of S. salicifolia reduced the growth of leukemia mouse lymphoma cells L5178Y to 23.8%. Keywords: flavonoids; Saussurea salicifolia; anticancer activity; Dionex HPLC-DAD system INTRODUCTION several species of Saussurea by other scientists in the world have revealed the presence of interest- Saussurea salicifolia is a medicinal plant belong- ing bioactive compounds like flavonoids (Jiang ing to genus of Saussurea of Asteraceae family. -
Regulation of Specific Target Genes and Biological Responses by Estrogen Receptor Subtype Agonists Leitman Et Al
COPHAR-861; NO. OF PAGES 8 Available online at www.sciencedirect.com Regulation of specific target genes and biological responses by estrogen receptor subtype agonists Dale C Leitman1, Sreenivasan Paruthiyil2, Omar I Vivar1, Elise F Saunier2, Candice B Herber1, Isaac Cohen2, Mary Tagliaferri2 and Terence P Speed3,4 Estrogenic effects are mediated through two estrogen receptor adverse effects. The most troublesome side-effect of (ER) subtypes, ERa and ERb. Estrogens are the most estrogens is the increased risk of breast and endometrial commonly prescribed drugs to treat menopausal conditions, cancer [1,2]. Estrogens also increase blood clotting that but by non-selectively triggering both ERa and ERb pathways can lead to venous thromboembolisms, and possibly in different tissues they can cause serious adverse effects. The strokes and heart disease, particularly in older women different sizes of the binding pockets and sequences of their [1]. activation function domains indicate that ERa and ERb should have different specificities for ligands and biological responses Estrogens in hormone therapy (HT) were formulated that can be exploited for designing safer and more selective long before there was a significant understanding of estrogens. ERa and ERb regulate different genes by binding to the mechanism of action of estrogens. The identification different regulatory elements and recruiting different of ERa and ERb (Figure 1) and the crystal structures of transcription and chromatin remodeling factors that are their ligand binding domain (LBD), the discovery of a expressed in a cell-specific manner. ERa-selective and ERb- variety of coregulatory proteins involved in the genomic selective agonists have been identified that demonstrate that pathway and the demonstration of the nongenomic the two ERs produce distinct biological effects. -
Anticancer Activity of <Emphasis Type="Italic">Asparagus
J. Korean Soc. Appl. Biol. Chem. 54(2), 188-193 (2011) Article Anticancer Activity of Asparagus cochinchinensis Extract and Fractions in HepG2 Cells Mikyung Park1†, Myeong Sook Cheon2†, Seong Hwan Kim1, Jin Mi Chun2, A Yeong Lee2, Byeong Cheol Moon2, Taesook Yoon2, Byung Kil Choo3, and Ho Kyoung Kim2* 1Laboratory of Chemical Genomics, Pharmacology Research Center, Korea Research Institute of Chemical Technology, P.O.Box 107, Yuseong-gu, Daejeon 305-600, Republic of Korea 2Center of Herbal Resources Research, Korea Institute of Oriental Medicine, 483 Exporo, Daejeon 305-811, Republic of Korea 3Department of Crop Agriculture & Life Science, College of Agriculture & Life Science, Chonbuk National University, Jeonju 561-756, Republic of Korea Received October 18, 2010; Accepted January 4, 2010 Asparagus cochinchinensis Merrill (Liliaceae) has been traditionally used for the treatment of cancer in Korea and China, but its anticancer activity and underlying mechanism remain to be defined. Anticancer activities were investigated on fractions obtained from A. cochinchinensis 70% ethanol extract (ACE-EtOH) in human hepatocellular carcinoma HepG2 cells. Ethylacetate fraction from A. cochinchinensis extract (ACE-EA), more effective than other fractions, induced apoptosis of HepG2 (IC50=72.33±0.34 μg/mL), as revealed by apoptotic feature observation, increased capase-3 activity and Poly ADP ribose polymerase cleavage, and decreased expression of X-linked inhibitor of apoptosis protein in a dose-dependent manner. Protein levels of autophagy- related molecules, microtubule-associated protein 1 light chain 3 α and beclin 1, appeared to be induced by ACE-EA, suggesting ACE-EA exhibits anti-cancer activity with induction via both apoptosis and autophagy signaling pathways in HepG2 cells. -
A Cytotoxic C-Glycosylated Derivative of Apigenin from the Leaves Of
Revista Brasileira de Farmacognosia 26 (2016) 763–766 ww w.elsevier.com/locate/bjp Short communication A cytotoxic C-glycosylated derivative of apigenin from the leaves of Ocimum basilicum var. thyrsiflorum a,b,∗ c,d Mohamed I.S. Abdelhady , Amira Abdel Motaal a Pharmacognosy Department, Faculty of Pharmacy, Helwan University, Cairo, Egypt b Pharmacognosy Department, Faculty of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia c Pharmacognosy Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt d Pharmaceutical Biology Department, Faculty of Pharmacy and Biotechnology, German University in Cairo (GUC), Cairo, Egypt a b s t r a c t a r t i c l e i n f o Article history: The standardized 80% ethanolic extract of the leaves of Ocimum basilicum var. thyrsiflorum (L.) Benth., Received 12 February 2016 Lamiaceae, growing in KSA, exhibited a significant antioxidant activity compared to the ethyl acetate and Accepted 7 June 2016 butanol extracts, which was correlated to its higher phenolic and flavonoid contents. Chromatographic Available online 20 July 2016 separation of the 80% ethanol extract resulted in the isolation of ten known compounds; cinnamic acid, gallic acid, methylgallate, ellagic acid, methyl ellagic acid, apigenin, luteolin, vitexin, isovitexin, and 3 -O- Keywords: acetylvitexin. Compound 3 -O-acetylvitexin, a C-glycosylated derivative of apigenin, was isolated for the Ocimum basilicum first time from genus Ocimum. The 80% ethanolic extract and 3 -O-acetylvitexin showed significant cyto- HCT116 toxic activities against the HCT human colon cancer cell line [IC values 22.3 ± 1.1 and 16.8 ± 2.0 g/ml Cytotoxic 116 50 Antioxidant (35.4 M), respectively]. -
Influence of the Nuclear Hormone Receptor Axis in the Progression and Treatment of Hormone Dependent Cancers
Influence of the nuclear hormone receptor axis in the progression and treatment of hormone dependent cancers A dissertation submitted to the Division of Research and Advanced Studies at the University of Cincinnati in partial fulfillment of the requirements for the degree of Doctorate of Philosophy (Ph.D.) In the Department of Cell and Cancer Biology of the College of Medicine 2007 by Janet K. Hess-Wilson B.A., Wittenberg University, 2000 Committee Chair: Karen E. Knudsen, Ph.D. Abstract Due to its pivotal role in prostatic growth and survival, the androgen receptor (AR) is the primary target of disseminated prostate cancer (CaP), as achieved via androgen deprivation therapy (ADT). Unfortunately, ADT is circumvented by restoration of AR activity, resulting in ADT resistant tumors for which there is no alternate treatment option. Through multiple mechanisms, reactivation of the AR specifically underlies the progression to therapy resistant tumors. The environmentally prevalent endocrine disrupting compound (EDC), bisphenol A (BPA) is able to activate specific somatically mutated ARs commonly found in CaP, resulting in androgen-independent proliferation of CaP cells. To directly assess the effect of BPA on ADT, we used an in vivo xenograft model of CaP that expresses a BPA-sensitive mutant AR, and mimics standard human cytotoxic response to ADT, followed by subsequent tumor re-growth. When tumor- bearing animals were exposed to environmentally relevant levels of BPA during ADT, the tumors failed therapy more rapidly (compared to placebo controls), with AR re- activation and concomitant increased tumor cell proliferation. These data suggest that environmentally relevant exposure to EDCs may reduce the efficacy of mainline ADT for CaP. -
Multi-Discipline Review
CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 211801Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Office Director Cross Discipline Team Leader Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review NDA/BLA Multidisciplinary Review and Evaluation NDA 211801 IBSRELA (tenapanor) NDA/BLA Multidisciplinary Review and Evaluation Application Type New Drug Application (NDA) Application Number(s) 211801 (IND #108,732) Priority or Standard Standard Submit Date(s) 09/12/2018 Received Date(s) 09/12/2018 PDUFA Goal Date 09/12/2019 Division/Office Division of Gastroenterology and Inborn Errors Products (DGIEP)/ Office of Drug Evaluation III (ODE III) Review Completion Date 09/10/2019 Established/Proper Name Tenapanor (RDX5791; AZD1722) (Proposed) Trade Name Ibsrela Pharmacologic Class Sodium/hydrogen exchanger 3 (NHE3) inhibitor Code name Applicant Ardelyx, Inc. Dosage form Oral tablets Applicant proposed Dosing 50 mg orally twice daily Regimen Applicant Proposed Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in Indication(s)/Population(s) Adults Applicant Proposed 440630006 SNOMED CT Indication Disease Term for each Proposed Indication Recommendation on Approval Regulatory Action Recommended Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in Indication(s)/Population(s) Adults (if applicable) Recommended Dosing 50 mg orally twice daily Regimen i Version date: September 12, 2018 Reference ID: 4490899 NDA/BLA Multidisciplinary Review and Evaluation NDA 211801 IBSRELA